Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. CING
CING logo

CING Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Cingulate Inc (CING) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.290
1 Day change
9.22%
52 Week Range
9.310
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Cingulate Inc (CING) is not a strong buy for a beginner investor with a long-term focus at this time. The lack of positive financial performance, weak technical indicators, and absence of significant catalysts suggest holding off on this investment for now.

Technical Analysis

The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 54.605, suggesting no clear overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading near its pivot level (6.434) with resistance at 6.969 and support at 5.899. Overall, the technicals do not strongly support a buy signal.

Positive Catalysts

  • NULL. There is no recent news, no significant insider or hedge fund activity, and no recent congress trading data.

Neutral/Negative Catalysts

  • The company's financial performance is weak, with no revenue growth, a negative net income of -$7.34M (despite YoY improvement), and a declining EPS (-1.35, down 42.31% YoY). Additionally, the stock trend analysis suggests a likelihood of minor declines in the short term (-0.34% next day, -1.16% next week, -0.69% next month).

Financial Performance

In Q3 2025, the company reported no revenue growth (0% YoY) and a net income of -$7.34M, which improved by 77.94% YoY but remains negative. EPS dropped significantly to -1.35, down 42.31% YoY, indicating poor profitability metrics.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes are available for this stock.

Wall Street analysts forecast CING stock price to rise
3 Analyst Rating
Wall Street analysts forecast CING stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 8.510
sliders
Low
8
Averages
27.33
High
58
Current: 8.510
sliders
Low
8
Averages
27.33
High
58
Roth Capital
Boobalan Pachaiyappan
Buy
downgrade
$17 -> $16
AI Analysis
2025-11-18
Reason
Roth Capital
Boobalan Pachaiyappan
Price Target
$17 -> $16
AI Analysis
2025-11-18
downgrade
Buy
Reason
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.
Roth Capital
NULL
to
Buy
upgrade
$10 -> $17
2025-10-14
Reason
Roth Capital
Price Target
$10 -> $17
2025-10-14
upgrade
NULL
to
Buy
Reason
Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CING
Unlock Now

People Also Watch